| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| James Samuel Shannon | Director | 2026-03-26 | 5,000 | $8.79 | $43.95kBuy |
| Kevin M. Brennan | SVP FINANCE AND ACCOUNTING | 2026-01-02 | 1,826 | $0.64 | $1.17kSell |
| Christopher James Frankenfield | Chief Financial Officer | 2026-01-02 | 7,030 | $0.64 | $4.52kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Gilead Sciences Inc | 152.19% | 9,105,451 | $75.94M | Insider |
| Yekaterina Chudnovsky | 117.00% | 7,000,000 | $58.38M | Insider |
| Sv7 Impact Medicine Fund LP | 53.94% | 3,227,264 | $26.92M | Insider |
| Bain Capital Life Sciences Investors LLC | 46.89% | 2,805,413 | $23.40M | Insider |
| Atlas Venture Fund XI LP | 46.03% | 2,754,109 | $22.97M | Insider |
| James E. Flynn | 38.24% | 2,287,944 | $19.08M | Insider |
| Takeda Pharmaceutical Co Ltd | 24.66% | 1,475,121 | $12.30M | Insider |
| Rivervest Venture Fund IV LP | 24.09% | 1,441,444 | $12.02M | Insider |
| Rock Springs Capital Management LP | 21.00% | 1,256,472 | $10.48M | Insider |
| Bay City Capital LLC | 18.88% | 1,129,490 | $9.42M | Insider |